Effects of itraconazole on the plasma kinetics of quazepam and its two active metabolites after a single oral dose of the drug

Therapeutic Drug Monitoring

Volumn 25, Issue 4, 2003, Pages 473-477

  Kato, Kimiyasu ^a   Yasui Furukori, Norio ^b   Fukasawa, Takashi ^a   Aoshima, Toshiaki ^a   Suzuki, Akihito ^b   Kanno, Muneaki ^a   Otani, Koichi ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

Author keywords

Cytochrome P450 3A4; Itraconazole; Metabolism; Quazepam

Indexed keywords

7 CHLORO 5 (2 FLUOROPHENYL) 1,3 DIHYDRO 1 (2,2,2 TRIFLUOROETHYL) 2H 1,4 BENZODIAZEPIN 2 ONE; ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DRUG METABOLITE; HYPNOTIC AGENT; ITRACONAZOLE; MIDAZOLAM; NORFLUDIAZEPAM; PLACEBO; QUAZEPAM; TRIAZOLAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; EVALUATION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARAMETER; PHARMACOKINETICS; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BENZODIAZEPINES; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FLURAZEPAM; HALF-LIFE; HUMANS; HYPNOTICS AND SEDATIVES; ITRACONAZOLE; MALE; PSYCHOMOTOR PERFORMANCE; SLEEP;

EID: 0043269277     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200308000-00010     Document Type: Article

References (14)

1. Ankier SI, Goa KL. Quazepam: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in insomnia. Drugs. 1988;35:42-62.
2. 14C-quazepam in man. Drug Metab Dispos. 1985;13:25-29.
3. Sieghart W. Several new benzodiazepines selectively interact with a benzodiazepine receptor subtype. Neurosci Lett. 1983;38:73-78.
4. Hilbert JM, Iorio L, Moritzen V, et al. Relationships of brain and plasma levels of quazepam, flurazepam, and their metabolites with pharmacological activity in mice. Life Sci. 1986;39:161-168.
5. Yasui N, Otani K, Kaneko S, et al. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther. 1996;59:514-519.
6. Furukori H, Otani K, Yasui N, et al. Effect of carbamazepine on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Neuropsychopharmacology. 1998;18:364-369.
7. Yasui N, Kondo T, Otani K, et al. Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology (Berl). 1998;139:269-273.
8. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol. 1995;40:270-272.
9. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther, 1994;56:601-607.
10. Fujisaki H, Hirotsu K, Ogawa T, et al. Metabolism of quazepam and its metabolites in humans: identification of metabolic enzymes and evaluation of drug interaction in vitro. Xenobio Metab Dispos. 2001;16:558-568. (in Japanese)
11. Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokin Biopharm. 1996;24:475-490.
12. Hoddes E, Zarcone V, Smythe H, et al. Quantification of sleepiness: a new approach. Psychophysiology. 1973;10:431-436.
13. Yasui-Furukori N, Kondo T, Takahata T, et al. Effect of dietary fat content in meals on pharmacokinetics of quazepam. J Clin Pharmacol. 2002;42:1335-1340.
14. Heykants J, Van Peer A, Van de Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses. 1989;32 (suppl 1):67-87.